{
    "organizations": [],
    "uuid": "5462658de32aef4ff3ef1d2b0d37199f9018aa92",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dermira-qtrly-loss-per-share-134/brief-dermira-qtrly-loss-per-share-1-34-idUSASB0C739",
    "ord_in_thread": 0,
    "title": "BRIEF-Dermira Qtrly Loss Per Share $‍1.34​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - Dermira Inc:\n* DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* DERMIRA INC - ‍OLUMACOSTAT GLASARETIL TOPLINE PHASE 3 DATA EXPECTED Q1 2018​\n* DERMIRA INC QTRLY LOSS PER SHARE $‍1.34​ * DERMIRA INC QTRLY ‍COLLABORATION AND LICENSE REVENUE $1.3 MILLION VERSUS $22.5 MILLION​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-23T05:07:00.000+02:00",
    "crawled": "2018-02-23T15:45:09.030+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "dermira",
        "inc",
        "dermira",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "provides",
        "corporate",
        "update",
        "dermira",
        "inc",
        "glasaretil",
        "topline",
        "phase",
        "data",
        "expected",
        "q1",
        "dermira",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "dermira",
        "inc",
        "qtrly",
        "license",
        "revenue",
        "million",
        "versus",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}